Financial Survey: Scopus BioPharma (NASDAQ:SCPS) and Reliv’ International (OTCMKTS:RELV)

Profitability

This table compares Scopus BioPharma and Reliv’ International’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Scopus BioPharma	N/A	N/A	N/A
Reliv’ International	-0.61%	-1.89%	-1.31%

Earnings and Valuation

This table compares Scopus BioPharma and Reliv’ International”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scopus BioPharma	N/A	N/A	-$11.61 million	N/A	N/A
Reliv’ International	$35.06 million	0.11	-$440,000.00	($0.09)	-25.00

Reliv’ International has higher revenue and earnings than Scopus BioPharma.

Volatility & Risk

Scopus BioPharma has a beta of -0.14, meaning that its stock price is 114% less volatile than the S&P 500. Comparatively, Reliv’ International has a beta of -0.04, meaning that its stock price is 104% less volatile than the S&P 500.

Insider & Institutional Ownership

7.8% of Reliv’ International shares are held by institutional investors. 5.1% of Scopus BioPharma shares are held by company insiders. Comparatively, 30.0% of Reliv’ International shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Reliv’ International beats Scopus BioPharma on 5 of the 8 factors compared between the two stocks.

About Scopus BioPharma

Scopus BioPharma Inc., a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases with unmet medical needs. It offers Duet Platform, which consists of signal transducer and activator of transcription 3 (STAT3), a master immune checkpoint inhibitor and toll-like receptor 9 (TLR9), as well as includes CpG-STAT3ASO (DUET-02), CpG-STAT3siRNA (DUET-01), and CpG-STAT3decoy (DUET-03); and that develops a suite of bifunctional oligonucleotides that activate antigen-presenting cells (APCs) in the tumor microenvironment that alleviates tumor immunosuppression to jump-start T cell-mediated immune responses. The company is also developing DUET-01, as a monotherapy targeting B-cell non-Hodgkin lymphoma; DUET-02 that provides systemic delivery for treatment of solid tumors comprising prostate or kidney cancers; and DUET-03, which targets the actual STAT3 transcription factor protein. Scopus BioPharma Inc. has licensing agreements with the City of Hope, National Institutes of Health Program, and The Hebrew University of Jerusalem. The company was formerly known as Project18 Inc. and changed its name to Scopus BioPharma Inc. in December 2017. Scopus BioPharma Inc. was incorporated in 2017 and is headquartered in New York, New York.

About Reliv’ International

Reliv' International, Inc. develops and markets nutritional supplements that address basic nutrition, specific wellness needs, weight management, and sports nutrition. The company's basic nutritional supplements are formulated to provide a balanced and complete level of supplementation for the consumer. Its principal products include Reliv Classic, Reliv Now, Innergize!, and FibRestore along with LunaRich X capsules. The company markets and sells its products through a direct selling system of independent distributors in the United States, Australia, Austria, Canada, France, Germany, Indonesia, Ireland, Malaysia, Mexico, the Netherlands, New Zealand, the Philippines, and the United Kingdom. Reliv' International, Inc. was founded in 1988 and is headquartered in Chesterfield, Missouri.